Patent · US Active

Factor X binders enhancing FX activation

US11787874B2 · kind B2 · utility

1Cited by

2References

7Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Jacob Lund · Roskilde, DK
Karina Thorn · Farum, DK
Mikkel Nors Harndahl · Roskilde, DK
Marie-Ange Buyse · Merelbeke, BE
Evelyn De Tavernier · Deurle, BE
Soren Steffensen · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE

Key dates

Filing date	Nov 15, 2018
Grant date	Oct 17, 2023
Priority date	—
Expiry date	Nov 15, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.